At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 212 enrolled
Drug / intervention
Dulaglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week Multicenter, Open-label, Single-arm Study to Evaluate Safety in Patients With Type 2 Diabetes Mellitus in India Treated With Dulaglutide
In Brief
A Phase 4 clinical trial evaluating Dulaglutide for Diabetes Mellitus, Type 2. Completed, enrolled 212 participants across 7 sites.
Detailed Summary
The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedDec 2022
Enrollment StartDec 2022
Primary CompletionJan 2024
TodayJul 2026
First PostedDec 21, 2022
Enrollment StartDec 29, 2022
Primary CompletionJan 16, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 3.5 years ago
Interventions
Dulaglutidedrug
Administered SC